English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

The rapid advance of generative AI is reshaping the strategic vision for R&Dacross industries. The unique challenges of pharmaceutical R&D will seeapplications of generative AI deliver value along the entire value chain fromearly discovery to regulatory approval. This perspective reviews thesechallenges and takes a three-horizon approach to explore the generative AIapplications already delivering impact, the disruptive opportunities which arejust around the corner, and the longer-term transformation which will shape thefuture of the industry. Selected applications are reviewed for their potentialto drive increase productivity, accelerate timelines, improve the quality ofresearch, data and decision making, and support a sustainable future for theindustry. Recommendations are given for Pharma R&D leaders developing agenerative AI strategy today which will lay the groundwork for getting realvalue from the technology and safeguarding future growth. Generative AI istoday providing new, efficient routes to accessing and combining organisationaldata to drive productivity. Next, this impact will reach clinical development,enhancing the patient experience, driving operational efficiency, and unlockingdigital innovation to better tackle the future burden of disease. Looking tothe furthest horizon, rapid acquisition of rich multi-omics data, which capturethe 'language of life', in combination with next generation AI technologieswill allow organisations to close the loop around phases of the pipelinethrough rapid, automated generation and testing of hypotheses from bench tobedside. This provides a vision for the future of R&D with sustainability atthe core, with reduced timescales and reduced dependency on resources, whileoffering new hope to patients to treat the untreatable and ultimately curediseases.

New Horizons: Pioneering Pharmaceutical R&D with Generative AI from lab to the clinic -- an industry perspective